SAN DIEGO, Nov. 4, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR)(TSX:TLB) expects to announce its third quarter 2009 financial results after the market closes on Thursday, November 12, 2009. OccuLogix is pleased to invite all interested parties to participate in a conference call during which the financial results will be discussed. The call will be held on November 12, at 4:30p.m. Eastern Time at 800-311-0799 (within the United States and Canada).

 Date:  November 12, 2009
 Time:  4:30 PM ET

Listen via Internet: http://www.tearlab.com/us/shareholder.htm/

Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=39689&k=8C537C6C

 Toll-free:     1-800-311-0799
 International: 1-719-955-9039

The call will be broadcast live at http://investor.shareholder.com/media/eventdetail.cfm?eventid=74622&CompanyID=TEAR&e=1&mediaKey=EDDE19B7CCF05968104464D9ECD2AD4C and archived on the company's web-site at www.tearlab.com under the "webcasts" link in the investor Relations section.

About OccuLogix, Inc. dba TearLab Corporation

OccuLogix dba TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. TearLab received the CE Mark for its TearLab(TM) Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 17 countries including the U.S.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding the growth of the market for dry eye disease products, the impact of our product on the management of affected patients, and our intention to seek CLIA Waiver. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT:  TearLab Corporation 
          Tracy Puckett, V.P. Marketing
            678-566-3829
            tpuckett@tearlab.com
          William Dumencu, CFO & Treasurer
            905-636-0128
            bdumencu@tearlab.com